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Background: University students have high rates of pharyngeal carriage of Neisseria meningitidis.
Interruption of carriage acquisition is an important mechanism of vaccines for inducing herd protection.
4CMenB and MenACWY-CRM vaccines have been shown to be immunogenic against meningococcal ser-
ogroups B and ACWY respectively in younger age groups, and also to elicit a modest impact on meningo-
coccal carriage in vaccinated students. However, vaccine responses in university students and the impact
of serum bactericidal antibody (SBA) titers on meningococcal carriage are undetermined.
Methods: Immunogenicity of two 4CMenB doses or one MenACWY-CRM dose was measured in univer-
sity students at Months 2, 4, 6 and 12 post-first vaccination. Immunogenicity of one MenACWY-CRM dose
in students with previous meningococcal serogroup C conjugate vaccination was also assessed. Immune
responses were measured with an SBA assay using human complement (hSBA) against three reference
strains for serogroup B and against one strain for each for serogroups C and Y. Correlations between
hSBA titers and meningococcal carriage were analyzed.
Results: All subjects demonstrated robust functional antibody responses to both vaccines at Month 2 and
a high proportion maintained protective hSBA titers up to Month 12. At baseline, carriage of disease-
associated serogroup B strains and serogroups C and Y were higher in subjects with already-protective
hSBA titers. Post-vaccination, while both 4CMenB and MenACWY-CRM elicited robust immunogenicity
in students, significant correlations between post-vaccination hSBA titers and carriage of disease-
associated serogroups were not observed.
Conclusions: 4CMenB and MenACWY-CRM were both highly immunogenic. There was no correlation
between carriage and post-vaccination hSBA titers.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Invasive meningococcal disease (IMD) is most common in
infants and children, but there is a second peak of incidence in
young adults –particularly those in higher education [1,2] – who
have relatively high case fatality rates [3,4] and morbidity [5].
428 R.C. Read et al. / Vaccine 35 (2017) 427–434While IMD is generally rare (<1 per 100,000 cases per annum in
Europe [6,7]), rates of asymptomatic nasopharyngeal carriage of
Neisseria meningitidis by healthy students living in close quarters
are commonly up to 35% [8–12]. This can lead to isolated outbreaks
of meningococcal disease, as have recently occurred in US univer-
sities [13,14].
In Europe, America and Asia, most IMD cases are due to ser-
ogroups B, C, Y [4] and increasingly W [15]. Capsular
polysaccharide-protein conjugate vaccines (e.g. against serogroups
A, C, W and Y) provide direct protection to vaccinated individuals
against IMD. They also have the added effect of reducing acquisi-
tion of new carriage to induce herd protection [16–18], although
the mechanism is undetermined.
Of the vaccines currently available, MenACWY-CRM (MenveoTM,
GSK Vaccines, Italy) is a polysaccharide-CRM197 conjugate vaccine
that has been shown to be immunogenic against serogroups A, C,
W and Y, well tolerated in all age groups [19–28], and approved
for use in individuals aged 2 months up to at least 55 years.
Another vaccine against serogroup B strains (4CMenB; BexseroTM,
GSK Vaccines, Italy) is approved in the European Union for use in
individuals over 2 months of age and has recently been deployed
in the UK infant schedule. 4CMenB includes factor H binding pro-
tein (fHbp), Neisseria adhesin A (NadA), and Neisserial Heparin
Binding Antigen (NHBA) combined with outer membrane vesicles
(OMV) from the New Zealand outbreak strain NZ98/254 [19].
4CMenB is immunogenic with an acceptable safety profile [29]
and predicted to be protective against a substantial proportion of
serogroup B strains currently circulating worldwide [20,21].
Recently, we reported that vaccination of students with
MenACWY-CRM and 4CMenB reduced overall meningococcal car-
riage over one-year follow-up. Specifically, 4CMenB vaccination
was estimated to result in a 27% reduction in carriage of capsular
groups BCWY; and MenACWY-CRM was estimated to reduce car-
riage of serogroups CWY by 36% [24]. Here, we report the immuno-
genicity endpoints for each vaccine in the same student cohort,
including a subset who received a prior dose of a meningococcal
serogroup C conjugate vaccine during the UK catch-up vaccination
campaigns in the early 2000s [25]. In addition, correlations
between serum bactericidal antibody (SBA) titers and carriage of
capsular groups BCY in all groups were calculated.2. Methods
2.1. Subjects
Healthy 18–24 year-old students of both genders were enrolled
and randomized 1:1:1 to receive two doses of 4CMenB (4CMenB
group), one dose of MenACWY-CRM plus a saline placebo
(MenACWY-CRM group), or two doses of a Japanese encephalitis
(JE) vaccine (Control group). Inclusion and exclusion criteria have
been described previously by Read et al. [24], who reported pri-
mary and secondary results of the trial (carriage rates at 1 month
and 1 year post-vaccination and safety data). The present report
focuses on the secondary immunogenicity outcomes of the same
trial registered at ClinicalTrial.gov (NCT01214850). Immunogenic-
ity assessments were planned in the first 200 study participants
enrolled in each group at the Sheffield University Hospital site,
out of the total of 2968 subjects enrolled in the study.2.2. Vaccines
Vaccines administered in the study were: 4CMenB, MenACWY-
CRM, and a JE vaccine (inactivated, adsorbed; Ixiaro, Valneva Aus-
tria, lot number JEV09L38A). 4CMenB (lot number 090101V) was
supplied as a liquid suspension in a pre-filled, single-dose syringe.MenACWY-CRM (lot number M10076) was prepared immediately
prior to administration by mixing the lyophilized MenA-CRM com-
ponent with the liquid MenCWY-CRM component. Subjects in the
MenACWY-CRM group also received one dose of a saline placebo
containing 1.5 mg aluminum hydroxide at a subsequent visit. The
JE vaccine was supplied as a liquid suspension in a pre-filled,
single-dose syringe.
All vaccines were administered as 0.5 mL doses injected intra-
muscularly into the deltoid region by designated unblinded staff
who did not participate in evaluations.
2.3. Immunogenicity
Blood samples (620 mL) were obtained immediately prior to
the first vaccination (Day 1) and at subsequent visits at Months
2, 4, 6 and 12 post-first injection (Fig. 1).
Immunogenicity of 4CMenB or MenACWY-CRM were assessed
by SBA assay using human complement (hSBA) against three refer-
ence strains for serogroup B (selected to assess responses specific
to vaccine antigens: 44/76-SL for fHbp, 5/99 for NadA, and
NZ98/254 for PorA [an immunodominant protein of OMVs]) and
against a strain each for serogroups C and Y. Table 1 presents geno-
typic and phenotypic information regarding the indicator strains
for serogroups B, C and Y. Carriage of serogroups A and W was
undetectable or low in this study (as expected [30]) and immuno-
genicity against them was not assessed.
Data for serogroup B were expressed as the percentage of sub-
jects with hSBA titersP4 (previously defined as a serologic corre-
late indicative of protection) and hSBA geometric mean titers
(GMTs) [26]. For serogroups C and Y, the percentage of subjects
with hSBA titers P8, hSBA GMTs, and the percentage of subjects
with seroresponse at Month 2 (one month post-second injection;
Fig. 1) were assessed. Seroresponse was defined as an increase from
hSBA titers <4 pre-vaccination toP8 post-vaccination, or as aP4-
fold increase for subjects with pre-vaccination hSBA titersP4.
Analyses were conducted on the immunogenicity subset of the
pre-specified modified intention-to-treat (MITT) population, which
included subjects having received a study vaccination, provided at
least one evaluable serum sample and had results for at least one
serogroup beyond baseline. The subjects and timepoints evaluated
varied with the serogroup analyzed. In the 4CMenB group,
immunogenicity against serogroup B and Y strains was assessed
for all subjects, while immunogenicity against serogroup C was
assessed in a random subset of 50 subjects. In the MenACWY-
CRM group, immunogenicity was evaluated for all subjects for ser-
ogroups C and Y, and in a random subset of 50 subjects for ser-
ogroup B strains. In the Control group, a random subset of 50
subjects was generated for immunogenicity assessments against
serogroup B and C. Immunogenicity against serogroup Y was
assessed for all subjects in each group, as higher rates of carriage
were expected.
Immunogenicity of one MenACWY-CRM dose against ser-
ogroups C and Y was evaluated in subjects with documented evi-
dence (from a physician) of previous vaccination with
meningococcal serogroup C glycoconjugate vaccine.
The effects of 4CMenB and MenACWY-CRM on N. meningitidis
carriage were recently reported [24] and new acquisition of car-
riage was defined as the post-vaccination detection of an N. menin-
gitidis isolate in a subject who had lacked it at baseline. Similarly,
displacement of carriage was defined as the post-vaccination loss
of an N. meningitidis isolate in a subject. In the present study, cor-
relations between meningococcal carriage (as assessed in [24]) and
pre- and post-vaccination hSBA titers were investigated. Accord-
ingly, the percentage of subjects with carriage of potentially viru-
lent serogroup B sequence type strains (identified as those
causing disease in the UK in 2006–2010) was evaluated. Subjects
Fig. 1. Subject disposition flowchart (modified intention-to-treat (MITT) immunogenicity subset; per protocol (PP).
Table 1
4CMenB vaccine antigen genotypic and phenotypic characteristics of serogroups B, C and Y reference strains.
Serogroup (test strain) Vaccine antigen molecular typinga PorA match MATS relative potencyb
fHbp NHBA NadA fHbp NHBA NadA
Serogroup B
5/99 2.p0023 20 + No <LLOQ 0.179 1.089
44/76-SL 1.p0001 3  No 1.006 0.352 <LLOQ
NZ98/254 1.p0014 2  Yes 0.044 0.847 <LLOQ
Serogroup C (C11) 2.22 15 + No <LLOQ 0.420 0.028
Serogroup Y (860800) 2.23 9  No <LLOQ 0.068 <LLOQ
LLOQ: Lower Limit of Quantitation.
a The fHbp variant/subvariant, NHBA peptide and presence (‘‘+”) of the nadA gene are shown for each strain. The fHbp nomenclature used to describe the different variants
and sub-variants of fHbp use a prefix (1, 2, or 3) that defines the variant and a suffix (e.g. 16) that defines the subvariant (or ‘‘peptide”) and distinguishes each by as little as a
single amino acid change and is consistent with the nomenclature used in the Neisseria PubMLST database (http://pubmlst.org/neisseria/). The 4CMenB vaccine includes fHbp
subvariant 1.1, NHBA subvariant 1.2, NadA subvariant 3.1, and PorA subtype P1.4.
b Meningococcal Antigen Typing System (MATS) Relative Potency (RP) values are expressed relative to the reference strain for each antigen. The positive bactericidal
thresholds are as follows: fHBP = 0.021, NHBA = 0.29 and NadA = 0.009.31 Numbers in bold indicate a relative potency above the positive bactericidal threshold. The clinical
significance of the MATS RP for the non-serogroup B strains is unknown.
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ogroup B test strains. The percentages of subjects with carriage of
serogroups C and Y were also evaluated and stratified by pre-
vaccination titers <8 or P8 against each serogroup. Carriage rates
were assessed as described previously [24].
2.4. Statistical analyses
Analyses were performed on per protocol data. No formal statis-
tical hypotheses were tested and all hSBA results were analyzed
descriptively. The percentage of subjects with hSBA titers above
the pre-specified thresholds, and with seroresponse against ser-ogroups C and Y were calculated by group and timepoint, with
associated 95% Clopper-Pearson confidence intervals (CIs). The
hSBA GMTs and two-sided 95% CIs were calculated by exponenti-
ating the corresponding log-transformed means (or mean differ-
ences from baseline in log-transformed titers) and their 95% CIs
for the log-transformed means obtained from a two-way analysis
of variance, accounting for vaccine group. Titers below detection
limit were set to half the limit.
To explore correlations between hSBA titers following 4CMenB
and MenACWY-CRM vaccinations and persistence of carriage of N.
meningitidis, hSBA results and the percentage of seropositive
subjects both with and without pharyngeal carriage for each sero-
430 R.C. Read et al. / Vaccine 35 (2017) 427–434group/4CMenB reference strain were calculated with 95% CIs. Chi-




A total of 592 subjects were included in this immunogenicity
investigation, and 585 subjects meeting entry criteria were
included in the MITT population. Exclusions were primarily due
to missed vaccinations or blood draw at Month 2. The students’
mean age was 20.2 years, 53% of participants were female, and
the majority were Caucasian. Demographic characteristics at base-
line were well matched across groups (Table 2).
3.2. Immune responses against serogroup B test strains
At baseline, high percentages of subjects across groups had
hSBA titers P4 against all three serogroup B test strains (Fig. 2A):
44/76-SL (fHbp: 62–71%), 5/99 (NadA: 45–60%), and NZ98/254
(PorA: 38–57%). By Month 2, 99–100% subjects in the 4CMenB
group had hSBA titers P4 against all the serogroup B test strains,Table 2
Demographics and baseline characteristics of subjects included in the modified intention-
4CMenB MenAC
N = 192 N = 192
Age (Years ± SD) 20.2 ± 1.7 20.2 ± 1
Males, n (%) 91 (47) 98 (51)
Ethnic origin, n (%)
Asian 10 (5) 11 (6)
Black 3 (2) 5 (3)
Caucasian 177 (92) 165 (86
Hispanic 1 (<1) 2 (1)
Other 1 (<1) 9 (5)
Weight (kg ± SD) 68.8 ± 13.1 68.6 ± 1
Height (cm ± SD) 172.7 ± 9.3 173.6 ±
Fig. 2. Immunogenicity against serogroup B test strains. (A) Percentage of subjects (95% C
(44/76-SL), NadA (5/99), and PorA (NZ98/254) at Day 1 (baseline) and Months 2, 4, 6 and
(modified intention-to-treat (MITT) immunogenicity subset; hSBA – serum bactericidaland a high proportion of these subjects maintained titers P4 up
to Month 12 (85–97%). In the MenACWY-CRM and Control groups,
the percentage of subjects with hSBA titersP4 against serogroup B
test strains remained within the same ranges at baseline and each
post-vaccination timepoint (Fig. 2A).
Post-vaccination, increases in hSBA GMTs against serogroup B
test strains were consistent with the increased percentage of sub-
jects with hSBA titers P4 against serogroup B test strains in each
group (Fig. 2B). Namely, one month after the second vaccination
in the 4CMenB group (Month 2), there was an increase in hSBA
GMTs relative to baseline (16- to 66-fold). Over the subsequent
ten months, while hSBA GMTs decreased (Fig. 2B), they were still
elevated compared to the level associated with seroprotection
(P4). In contrast, hSBA GMTs in the MenACWY-CRM and Control
groups remained at baseline level for each of the serogroup B ref-
erence strains at all post-vaccination timepoints.3.3. Immune responses against serogroups C and Y
At baseline (Day 1; Fig. 3), the majority of subjects across study
groups had hSBA titers P8 against serogroups C (80–90%) and Y
(72–78%; see Fig. 3A and B). Post-vaccination, a high percentage
of subjects in all groups maintained hSBA titers P8 against ser-to-treat (MITT) immunogenicity subset.
WY-CRM Control Total
N = 197 N = 581
.5 20.2 ± 1.7 20.2 ± 1.6
86 (44) 275 (47)
11 (6) 32 (6)
2 (1) 10 (2)
) 170 (86) 512 (88)
1 (<1) 4 (<1)
13 (7) 23 (4)
4.4 67.5 ± 13.6 68.3 ± 13.7
10.1 171.7 ± 9.7 172.7 ± 9.7
I) with hSBA titersP4 and (B) hSBA GMTs against serogroup B test strains for fHbp
12 (1, 3, 5, and 11 months following the second vaccination, respectively), by group
antibody assay with human complement; GMT – geometric mean titers).
Fig. 3. Immunogenicity against serogroups C and Y. (A) Percentage of subjects (95% CI) with hSBA titersP8 and hSBA GMTs (95% CI) against serogroup C at Day 1 (baseline)
and Months 2 and 12 (1 and 11 months following the second vaccination/placebo injection, respectively), by group and in those subjects in the MenACWY-CRM group with
documentation of prior meningococcal serogroup C vaccination. (B) Percentage of subjects (95% CI) with hSBA titersP8 and hSBA GMTs (95% CI) against serogroup Y at Day 1
(baseline) and Months 2, 4, 6, and 12 (1, 3, 5, and 11 months following the second vaccination/placebo injection, respectively), by group and in those subjects in the
MenACWY-CRM group with documentation of prior meningococcal serogroup C vaccination. (modified intention-to-treat (MITT) immunogenicity subset; hSBA – serum
bactericidal antibody assay with human complement; GMT – geometric mean titers).
R.C. Read et al. / Vaccine 35 (2017) 427–434 431ogroup C (Fig. 3A). The percentage of subjects with hSBA titersP8
against serogroup Y remained under 85% at each post-vaccination
timepoint, in all groups except the ones receiving MenACWY-CRM
(Fig. 3B).
Baseline GMTs against serogroups C and Y were similar across
groups (Fig. 3). At Month 2, however, while hSBA GMTs against ser-
ogroup C and Y strains in the Control group remained at baseline
levels, the MenACWY-CRM group showed a 26- and 4-fold increase
in GMTs against serogroups C and Y, respectively, at Month 2 after
a single dose of MenACWY-CRM.
One month after completing the 4CMenB vaccine course (at
Month 2), 2- and 1.5-fold increases in hSBA GMTs against ser-
ogroups C and Y, respectively, were observed in the 4CMenB group.3.4. Immune responses against serogroups C and Y in prior recipients
of meningococcal C vaccine
At baseline, 93% and 80% of subjects in the MenACWY-CRM
group with prior record of a MenC vaccination had hSBA titers
P8 against serogroups C and Y, respectively. Two months after
receiving a single MenACWY-CRM vaccination in this study, 100%
and 96% of subjects achieved hSBA titers P8 against serogroups
C and Y, respectively. There was also high antibody persistence
with 100% and 91% subjects still maintaining hSBA titers P8 at
11 months post-vaccination against serogroups C and Y, respec-
tively (see Fig. 3). hSBA GMTs in the MenACWY (with prior MenC)
and Control groups were similar at baseline. At Month 2, hSBA
432 R.C. Read et al. / Vaccine 35 (2017) 427–434GMTs in the Control group did not change, while hSBA GMTs
against serogroups C and Y in the MenACWY group increased by
8 and 4-fold, respectively (Fig. 3). At Month 2, 147 of 181 subjects
achieved a seroresponse against serogroup C (81% [95% CI: 75–
87%]); whereas seroresponse rates against serogroup Y were mod-
est (44% [95% CI: 37–52%]). In contrast, the 4CMenB and Control
groups showed low seroresponse rates against serogroups C (8%
[95% CI: 2–20%] and 4% [95% CI: 1–14%], respectively) and Y (12%
[95% CI: 8–17%] and 7% [95% CI: 4–12%], respectively).3.5. Carriage of N. meningitidis and seroresponses
At baseline, carriage rates for potentially virulent serogroup B
strains, and for serogroups C and Y were higher in subjects with
hSBA titers above the pre-specified threshold for each serogroup
(Table 3). Contrastingly in 4CMenB group, post-vaccination at
Month 12, there was a trend of subjects with baseline hSBA < 4
to be associated with higher rates of carriage when compared to
subjects with hSBAP 4. Additionally, serogroup-specific immune
responses among MenACWY-CRM recipients appeared to differ
(p < 0.001, post hoc analysis) depending on whether or not theyTable 3
Percentage of subjects with carriage of ‘disease-associated’ capsular group B sequence types
baseline (Day 1), 1 month post-first vaccination (Month 1), and 1, 3, 5, and 11 months post
control groups and the percentage of subjects with carriage of serogroups CWY strains stra
baseline (Day 1), 1 month post-first vaccination (Month 1), and 1, 3, 5, and 11 months post
CRM and control groups.
Pre-vaccination hSBA titer <4
4CMenB Control
Serogroup B test strain n/N (%; 95% CI) n/N (%; 9
44/76-SL (fHbp)
Day 1 0/60 (0; 0–6) 0/19 (0;
Month 1 2/60 (3; 0–12) 0/18 (0;
Month 2 4/60 (7; 2–16) 0/18 (0;
Month 4 2/56 (4; 0–12) 0/17 (0;
Month 6 4/56 (7; 2–17) 0/17 (0;
Month 12 6/56 (11; 4–22) 0/16 (0;
5/99 (NadA)
Day 1 4/77 (5; 1–13) 2/23 (9;
Month 1 3/77 (4; 1–11) 2/23 (9;
Month 2 5/77 (6; 2–15) 0/22 (0;
Month 4 3/71 (4; 1–12) 2/21 (10
Month 6 2/68 (3; 0–10) 2/21 (10
Month 12 5/71 (7; 2–16) 1/20 (5;
NZ98/254 (PorA)
Day 1 2/83 (2; 0–8) 2/31 (6;
Month 1 3/81 (4; 1–10) 2/30 (7;
Month 2 3/81 (4; 1–10) 0/30 (0;
Month 4 2/75 (3; 0–9) 1/29 (3;
Month 6 2/70 (3; 0–10) 1/29 (3;
Month 12 8/75 (11; 5–20) 1/28 (4;
Pre-vaccination hSBA titer <8
MenACWY-CRM Control
n/N (%; 95% CI) n/N (%; 9
Serogroup C
Day 1 0/26 (0; 0–13) 0/10 (0;
Month 1 0/24 (0; 0–14) 0/9 (0; 0
Month 2 1/24 (4; 0–21) 0/8 (0; 0
Month 4 1/21 (5; 0–24) 0/7 (0; 0
Month 6 0/22 (0; 0–15) 0/7 (0; 0
Month 12 3/21 (14; 3–36) 0/7 (0; 0
Serogroup Y
Day 1 0/42 (0; 0–8) 0/44 (0;
Month 1 0/39 (0; 0–9) 1/40 (3;
Month 2 0/39 (0; 0–9) 0/40 (0;
Month 4 0/36 (0; 0–10) 1/37 (3;
Month 6 0/36 (3; 0.1–15) 2/35 (6;
Month 12 1/34 (3; 0.1–15) 2/35 (6;were carrying a serogroup Y strain at baseline. Specifically, at
Month 2, following one vaccination with MenACWY-CRM, 76 of
174 non-carriers (44% [95% CI: 36–51%]) achieved a 4-fold increase
in hSBA titers for serogroup Y (seroresponse) compared with 0 of 7
carriers (0% [95% CI: 0–41%]).
The immune responses elicited against serogroups C and Y after
one dose of MenACWY-CRM persisted up to Month 12 post-
vaccination. No clear correlation between carriage rates and
post-vaccination antibodies was shown against 4CMenB reference
strains or serogroups C and Y.4. Discussion
This study showed that robust immune responses against ser-
ogroup B reference strains were elicited with 4CMenB, and against
serogroups C and Y with MenACWY-CRM, from one month and for
up to at least 11 months post-vaccination of students. There was
no clear correlation between changes in carriage rates and post-
vaccination bactericidal antibody levels.
The immunogenicity results following two doses of 4CMenB in
the present study are consistent with a previous study in high, stratified by pre-vaccination hSBA titer <4 andP4 against serogroup B test strains at
-second vaccination/injection (Months 2, 4, 6 and 12, respectively) in the 4CMenB and
tified by pre-vaccination hSBA titers <8 andP8 against serogroup C or serogroup Y at
-second vaccination/injection (Months 2, 4, 6 and 12, respectively) in the MenACWY-
Pre-vaccination hSBA titer P4
4CMenB Control
5% CI) n/N (%; 95% CI) n/N (%; 95% CI)
0–18) 13/133 (10; 5–16) 2/31 (6; 1–21)
0–19) 7/130 (5; 2–11) 3/30 (10; 2–27%)
0–19) 10/130 (8; 4–14) 2/30 (7; 1–22)
0–20) 11/120 (9; 5–16) 4/29 (14; 4–32)
0–20) 6/115 (5; 2–11) 3/28 (11; 2–28)
0–21) 6/123 (5; 2–10) 2/30 (7; 1–22)
1–28%) 9/116 (8; 4–14) 0/27 (0; 0–13)
1–29) 6/113 (5; 2–11) 1/26 (4; 0.1–20)
0–15) 9/113 (8; 4–15) 2/26 (8; 1–25)
; 1–30) 10/105 (10; 5–17) 2/25 (8; 1–26)
; 1–30) 8/103 (8; 3–15) 1/24 (4; 0–21)
0–25) 7/108 (6; 3–13) 1/26 (4; 0.1–20)
1–21) 11/110 (10; 5–7) 0/19 (0; 0–18)
1–22) 6/109 (6; 2–12) 1/18 (6; 0–27)
0–12) 11/109 (10; 5–17) 2/18 (11; 1–35)
0.1–18) 11/101 (11; 6–19) 3/17 (18; 4–43)
0.1–18) 8/101 (8; 3–15) 2/16 (13; 2–38)
0.1–18) 4/104 (4; 1–10) 1/18 (6; 0–27)
Pre-vaccination hSBA titer P8
MenACWY-CRM Control
5% CI) n/N (%; 95% CI) n/N (%; 95% CI)
0–31) 9/168 (5; 2–10) 3/40 (8; 2–20)
–34) 9/161 (6; 3–10) 4/40 (10; 3–24)
–37) 6/158 (4; 1–8) 3/40 (8; 2–20)
–41) 9/146 (6; 3–11) 5/37 (14; 5–29)
–41) 12/144 (8; 4–14) 3/33 (9; 2–24)
–41) 3/142 (2; 0–6) 1/35 (3; 0.1–15)
0–8) 9/152 (6; 3–11) 9/154 (6; 3–11)
0.1–13) 9/146 (6; 3–11) 8/151 (5; 2–10)
0–9) 7/143 (5; 2–10) 8/149 (5; 2–10)
0.1–14) 10/131 (8; 4–14) 10/139 (7; 4–13)
1–19) 12/130 (9; 5–16) 7/134 (5; 2–10)
1–19) 5/129 (4; 1–9) 4/135 (3; 1–7)
R.C. Read et al. / Vaccine 35 (2017) 427–434 433school students (aged 11–17 years), which showed that one month
after two doses of 4CMenB nearly all subjects reached hSBA titers
P4 against serogroup B reference strains [27]; however, baseline
titers were noticeably high. While the percentage of subjects in
the present study with baseline hSBA titers P4 against serogroup
B reference strains was even higher than that reported by Santo-
laya et al., the percentages were still lower than pre-vaccination
levels previously reported in UK adults [31]. These differences
likely reflect anthropological and geographic differences (UK/Chile)
and/or different carriage rates, which can act as a priming event
[28,32]. Irrespective of baseline immune status, all but one subject
in the 4CMenB group of the present study had hSBA titers P4
against the serogroup B strains one month after the two-dose ser-
ies, and at least 85% of subjects in this group maintained hSBA
titers P4 against each of the serogroup B strains over the subse-
quent 10 months. As expected, the percentage of subjects seropos-
itive against serogroup B strains did not increase over baseline in
either the MenACWY-CRM or Control groups at any post-
vaccination timepoint.
The results of the study also demonstrated that one dose of
MenACWY-CRM elicited robust immune responses against ser-
ogroups C and Y from Month 2 up to Month 12 post-vaccination.
This effect appeared even more pronounced in subjects who had
previously received a meningococcal serogroup C conjugate vacci-
nation. Similar immunogenicity results following one dose of
MenACWY-CRM have been reported in adolescents in other coun-
tries [27,33–35]. However, it is important to note that the Month 2
analysis point in this study is unusual for investigations of
MenACWY-CRM immunogenicity, which typically measure
responses one month post-vaccination. This discrepancy should
be considered when comparing the MenACWY-CRM results with
other studies.
Population-scale meningococcal serogroup C conjugate vaccina-
tion provides benefit not only through direct protection, but also
through the reduction of transmission [36]. Consistent with this,
our recent carriage analysis of 4CMenB and MenACWY-CRM [24]
demonstrated that 4CMenB has a broad–albeit modest–impact
on carriage of meningococcal strains, particularly serogroup Y, over
the course of one year follow-up [24]. The current study suggests
that hSBA cannot be used as a surrogate marker of carriage-
reduction efficacy of meningococcal vaccines or that the threshold
that disrupts carriage is different to that which elicits serological
protection against meningococcal disease [26]. Indeed, it has been
shown that greater concentrations of pneumococcal antibody is
required to impact carriage compared to that required to confer
immunity [37]. Ultimately, it is possible that mucosal or other
non-hSBA immune responses to 4CMenB components are more
critical for disrupting meningococcal carriage [36,38].
We found that carriage of serogroups by participants influenced
their serologic responses. There was a higher rate of serogroup B
carriage among subjects with hSBA titers P4 against serogroup B
strains at baseline, compared to subjects with titers <4 at baseline.
Similarly, there was a trend for higher carriage of serogroups C and
Y among subjects with hSBA titers P8 at baseline, compared to
subjects with titers <8 at baseline. While there was no clear asso-
ciation between carriage rates for serogroups B and C and post-
vaccination hSBA levels against these strains, there was evidence
of a decrease in immune response to the MenACWY-CRM vaccine
in subjects with baseline carriage of serogroup Y. This lowered
immune response, whilst based on a small sample, emulates previ-
ous reports of hyporesponsive effects to the pneumococcal conju-
gate vaccination in infants and children carrying pneumococcus
at the time of immunization [39–41]. Nevertheless, irrespective
of baseline hSBA titers or carriage status, two months after one
dose of MenACWY-CRM, 95% subjects in the MenACWY-CRM
group achieved hSBA titers P8 against serogroup Y.In summary, two doses of 4CMenB or one dose of MenACWY-
CRM elicited robust immune responses in university students. No
correlations between pharyngeal carriage and post-vaccination
hSBA titers were observed.Trademark
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